
Health authorities in Australia have officially added Foundayo (orforglipron) to the Australian Register of Therapeutic Goods, introducing a major breakthrough in oral GLP-1 medication. Welcomed today by Diabetes Australia, the once-daily tablet provides a flexible, needle-free option for both type 2 diabetes treatment and chronic weight management in eligible adults. Unlike earlier oral therapies that require strict fasting or water limits, the Foundayo weight loss pill can be taken without food or water restrictions, simplifying daily adherence for patients.